parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.03 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in proximal tubule cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 76	0.91
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 6472

receipt 6480: RRN3 in dopamine neurons, braak

power: full sample +0.11 (p 0.671, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.683, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.591, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.27, sign flips 0; without severely affected donors +0.11 (p 0.671, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RRN3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 6479: RRN3 in oligodendrocytes, braak

power: full sample +0.03 (p 0.922, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.00 (p 0.997, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.09 (p 0.715, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.19, sign flips 9; without severely affected donors +0.03 (p 0.922, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RRN3 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts